ContraFect to Present at the 11th Annual BIO Investor Forum

YONKERS, NY--(Marketwire - Oct 3, 2012) - ContraFect Corporation, developing biotherapeutics for life-threatening infectious diseases, today announced that Julia P. Gregory, the Company's executive vice president and chief financial officer, and Barry Kappel, Ph.D., the Company's vice president of business development, will present a corporate overview at the 11^th Annual BIO Investor Forum taking place at the Palace Hotel in San Francisco, CA from October 9-10, 2012. Ms. Gregory and Dr. Kappel will discuss ContraFect's novel approach to drug resistant Staph infections and clinical plans for its lead product, CF-301. The Company's presentation will take place on Tuesday, October 9th at 9:00 am PDT. 

About BIO Investor Forum:

The 11th Annual BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-One partnering meetings.

About ContraFect:

ContraFect Corporation is a biotechnology company pioneering the use of Lysins and Monoclonal Antibodies to treat life-threatening infectious diseases. ContraFect's initial products include agents to treat diseases such as MRSA (drug-resistant staphylococcus bacteria) and influenza. Its scientific strategy focuses on the use of combination therapies, where it believes that the company's products will overcome high rates of mutation and resistance observed in microbes.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.